SEOM-GEIS clinical guideline for gastrointestinal stromal tumors (2022)

Gastrointestinal stromal tumor (GIST) is the most common malignant neoplasm of mesenchymal origin, and a paradigmatic model for a successful rational development of targeted therapies in cancer. The introduction of tyrosine kinase inhibitors with activity against KIT/PDGFRA in both localized and adv...

Full description

Saved in:
Bibliographic Details
Published in:Clinical & translational oncology 2023-09, Vol.25 (9), p.2707-2717
Main Authors: Serrano, César, Álvarez, Rosa, Carrasco, Juan Antonio, Marquina, Gloria, Martínez-García, Jerónimo, Martínez-Marín, Virginia, Sala, María Ángeles, Sebio, Ana, Sevilla, Isabel, Martín-Broto, Javier
Format: Article
Language:English
Subjects:
Clinical Guides in Oncology
Medicine
Medicine & Public Health
Oncology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c447t-cb238733d5f1860dd895741c3f98ddef73283404977a4de6d4760d69e2b3fd4f3
cites cdi_FETCH-LOGICAL-c447t-cb238733d5f1860dd895741c3f98ddef73283404977a4de6d4760d69e2b3fd4f3
container_end_page 2717
container_issue 9
container_start_page 2707
container_title Clinical & translational oncology
container_volume 25
creator Serrano, César
Álvarez, Rosa
Carrasco, Juan Antonio
Marquina, Gloria
Martínez-García, Jerónimo
Martínez-Marín, Virginia
Sala, María Ángeles
Sebio, Ana
Sevilla, Isabel
Martín-Broto, Javier
description Gastrointestinal stromal tumor (GIST) is the most common malignant neoplasm of mesenchymal origin, and a paradigmatic model for a successful rational development of targeted therapies in cancer. The introduction of tyrosine kinase inhibitors with activity against KIT/PDGFRA in both localized and advanced stages has remarkably improved the survival in a disease formerly deemed resistant to all systemic therapies. These guidelines are elaborated by the conjoint effort of the Spanish Society of Medical Oncology (SEOM) and the Spanish Sarcoma Research Group (GEIS) and provide a multidisciplinary and updated consensus for the diagnosis and treatment of GIST patients. We strongly encourage that the managing of these patients should be performed within multidisciplinary teams in reference centers.
doi_str_mv 10.1007/s12094-023-03177-7
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10425520</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2808588153</sourcerecordid><originalsourceid>FETCH-LOGICAL-c447t-cb238733d5f1860dd895741c3f98ddef73283404977a4de6d4760d69e2b3fd4f3</originalsourceid><addsrcrecordid>eNp9UctOwzAQtBCIlsIPcEA5lkPAr8TOCaGqlEpFPRTOVhrbwVUSFztB4u9xSanKhdPuamZnHwPANYJ3CEJ27xGGGY0hJjEkiLGYnYAhSrMsJjBJTo_yAbjwfgNDliJ0DgaEIZwxlA7BbDVdvsSz6XwVFZVpTJFXUdkZqUKhIm1dVOa-ddY0rfKtaQK8K-sQ2662zkdjDDG-vQRnOq-8utrHEXh7mr5OnuPFcjafPC7iglLWxsUaE84IkYlGPIVS8ixhFBVEZ1xKpRnBnFBIM8ZyKlUqKQusNFN4TbSkmozAQ6-77da1koVqWpdXYutMnbsvYXMj_iKNeRel_RQIUpwkGAaF8V7B2Y8uHCVq4wtVVXmjbOcF5pAnnKOEBCruqYWz3julD3MQFDsLRG-BCBaIHwsEC003xxseWn5_HgikJ_gANaVyYmM7Fz7r_5P9Bt4ZkP0</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2808588153</pqid></control><display><type>article</type><title>SEOM-GEIS clinical guideline for gastrointestinal stromal tumors (2022)</title><source>Springer Link</source><creator>Serrano, César ; Álvarez, Rosa ; Carrasco, Juan Antonio ; Marquina, Gloria ; Martínez-García, Jerónimo ; Martínez-Marín, Virginia ; Sala, María Ángeles ; Sebio, Ana ; Sevilla, Isabel ; Martín-Broto, Javier</creator><creatorcontrib>Serrano, César ; Álvarez, Rosa ; Carrasco, Juan Antonio ; Marquina, Gloria ; Martínez-García, Jerónimo ; Martínez-Marín, Virginia ; Sala, María Ángeles ; Sebio, Ana ; Sevilla, Isabel ; Martín-Broto, Javier</creatorcontrib><description>Gastrointestinal stromal tumor (GIST) is the most common malignant neoplasm of mesenchymal origin, and a paradigmatic model for a successful rational development of targeted therapies in cancer. The introduction of tyrosine kinase inhibitors with activity against KIT/PDGFRA in both localized and advanced stages has remarkably improved the survival in a disease formerly deemed resistant to all systemic therapies. These guidelines are elaborated by the conjoint effort of the Spanish Society of Medical Oncology (SEOM) and the Spanish Sarcoma Research Group (GEIS) and provide a multidisciplinary and updated consensus for the diagnosis and treatment of GIST patients. We strongly encourage that the managing of these patients should be performed within multidisciplinary teams in reference centers.</description><identifier>ISSN: 1699-3055</identifier><identifier>ISSN: 1699-048X</identifier><identifier>EISSN: 1699-3055</identifier><identifier>DOI: 10.1007/s12094-023-03177-7</identifier><identifier>PMID: 37129716</identifier><language>eng</language><publisher>Cham: Springer International Publishing</publisher><subject>Clinical Guides in Oncology ; Medicine ; Medicine &amp; Public Health ; Oncology</subject><ispartof>Clinical &amp; translational oncology, 2023-09, Vol.25 (9), p.2707-2717</ispartof><rights>The Author(s) 2023</rights><rights>2023. The Author(s).</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c447t-cb238733d5f1860dd895741c3f98ddef73283404977a4de6d4760d69e2b3fd4f3</citedby><cites>FETCH-LOGICAL-c447t-cb238733d5f1860dd895741c3f98ddef73283404977a4de6d4760d69e2b3fd4f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37129716$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Serrano, César</creatorcontrib><creatorcontrib>Álvarez, Rosa</creatorcontrib><creatorcontrib>Carrasco, Juan Antonio</creatorcontrib><creatorcontrib>Marquina, Gloria</creatorcontrib><creatorcontrib>Martínez-García, Jerónimo</creatorcontrib><creatorcontrib>Martínez-Marín, Virginia</creatorcontrib><creatorcontrib>Sala, María Ángeles</creatorcontrib><creatorcontrib>Sebio, Ana</creatorcontrib><creatorcontrib>Sevilla, Isabel</creatorcontrib><creatorcontrib>Martín-Broto, Javier</creatorcontrib><title>SEOM-GEIS clinical guideline for gastrointestinal stromal tumors (2022)</title><title>Clinical &amp; translational oncology</title><addtitle>Clin Transl Oncol</addtitle><addtitle>Clin Transl Oncol</addtitle><description>Gastrointestinal stromal tumor (GIST) is the most common malignant neoplasm of mesenchymal origin, and a paradigmatic model for a successful rational development of targeted therapies in cancer. The introduction of tyrosine kinase inhibitors with activity against KIT/PDGFRA in both localized and advanced stages has remarkably improved the survival in a disease formerly deemed resistant to all systemic therapies. These guidelines are elaborated by the conjoint effort of the Spanish Society of Medical Oncology (SEOM) and the Spanish Sarcoma Research Group (GEIS) and provide a multidisciplinary and updated consensus for the diagnosis and treatment of GIST patients. We strongly encourage that the managing of these patients should be performed within multidisciplinary teams in reference centers.</description><subject>Clinical Guides in Oncology</subject><subject>Medicine</subject><subject>Medicine &amp; Public Health</subject><subject>Oncology</subject><issn>1699-3055</issn><issn>1699-048X</issn><issn>1699-3055</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNp9UctOwzAQtBCIlsIPcEA5lkPAr8TOCaGqlEpFPRTOVhrbwVUSFztB4u9xSanKhdPuamZnHwPANYJ3CEJ27xGGGY0hJjEkiLGYnYAhSrMsJjBJTo_yAbjwfgNDliJ0DgaEIZwxlA7BbDVdvsSz6XwVFZVpTJFXUdkZqUKhIm1dVOa-ddY0rfKtaQK8K-sQ2662zkdjDDG-vQRnOq-8utrHEXh7mr5OnuPFcjafPC7iglLWxsUaE84IkYlGPIVS8ixhFBVEZ1xKpRnBnFBIM8ZyKlUqKQusNFN4TbSkmozAQ6-77da1koVqWpdXYutMnbsvYXMj_iKNeRel_RQIUpwkGAaF8V7B2Y8uHCVq4wtVVXmjbOcF5pAnnKOEBCruqYWz3julD3MQFDsLRG-BCBaIHwsEC003xxseWn5_HgikJ_gANaVyYmM7Fz7r_5P9Bt4ZkP0</recordid><startdate>20230901</startdate><enddate>20230901</enddate><creator>Serrano, César</creator><creator>Álvarez, Rosa</creator><creator>Carrasco, Juan Antonio</creator><creator>Marquina, Gloria</creator><creator>Martínez-García, Jerónimo</creator><creator>Martínez-Marín, Virginia</creator><creator>Sala, María Ángeles</creator><creator>Sebio, Ana</creator><creator>Sevilla, Isabel</creator><creator>Martín-Broto, Javier</creator><general>Springer International Publishing</general><scope>C6C</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20230901</creationdate><title>SEOM-GEIS clinical guideline for gastrointestinal stromal tumors (2022)</title><author>Serrano, César ; Álvarez, Rosa ; Carrasco, Juan Antonio ; Marquina, Gloria ; Martínez-García, Jerónimo ; Martínez-Marín, Virginia ; Sala, María Ángeles ; Sebio, Ana ; Sevilla, Isabel ; Martín-Broto, Javier</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c447t-cb238733d5f1860dd895741c3f98ddef73283404977a4de6d4760d69e2b3fd4f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Clinical Guides in Oncology</topic><topic>Medicine</topic><topic>Medicine &amp; Public Health</topic><topic>Oncology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Serrano, César</creatorcontrib><creatorcontrib>Álvarez, Rosa</creatorcontrib><creatorcontrib>Carrasco, Juan Antonio</creatorcontrib><creatorcontrib>Marquina, Gloria</creatorcontrib><creatorcontrib>Martínez-García, Jerónimo</creatorcontrib><creatorcontrib>Martínez-Marín, Virginia</creatorcontrib><creatorcontrib>Sala, María Ángeles</creatorcontrib><creatorcontrib>Sebio, Ana</creatorcontrib><creatorcontrib>Sevilla, Isabel</creatorcontrib><creatorcontrib>Martín-Broto, Javier</creatorcontrib><collection>SpringerOpen</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Clinical &amp; translational oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Serrano, César</au><au>Álvarez, Rosa</au><au>Carrasco, Juan Antonio</au><au>Marquina, Gloria</au><au>Martínez-García, Jerónimo</au><au>Martínez-Marín, Virginia</au><au>Sala, María Ángeles</au><au>Sebio, Ana</au><au>Sevilla, Isabel</au><au>Martín-Broto, Javier</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>SEOM-GEIS clinical guideline for gastrointestinal stromal tumors (2022)</atitle><jtitle>Clinical &amp; translational oncology</jtitle><stitle>Clin Transl Oncol</stitle><addtitle>Clin Transl Oncol</addtitle><date>2023-09-01</date><risdate>2023</risdate><volume>25</volume><issue>9</issue><spage>2707</spage><epage>2717</epage><pages>2707-2717</pages><issn>1699-3055</issn><issn>1699-048X</issn><eissn>1699-3055</eissn><abstract>Gastrointestinal stromal tumor (GIST) is the most common malignant neoplasm of mesenchymal origin, and a paradigmatic model for a successful rational development of targeted therapies in cancer. The introduction of tyrosine kinase inhibitors with activity against KIT/PDGFRA in both localized and advanced stages has remarkably improved the survival in a disease formerly deemed resistant to all systemic therapies. These guidelines are elaborated by the conjoint effort of the Spanish Society of Medical Oncology (SEOM) and the Spanish Sarcoma Research Group (GEIS) and provide a multidisciplinary and updated consensus for the diagnosis and treatment of GIST patients. We strongly encourage that the managing of these patients should be performed within multidisciplinary teams in reference centers.</abstract><cop>Cham</cop><pub>Springer International Publishing</pub><pmid>37129716</pmid><doi>10.1007/s12094-023-03177-7</doi><tpages>11</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1699-3055
ispartof Clinical & translational oncology, 2023-09, Vol.25 (9), p.2707-2717
issn 1699-3055
1699-048X
1699-3055
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10425520
source Springer Link
subjects Clinical Guides in Oncology
Medicine
Medicine & Public Health
Oncology
title SEOM-GEIS clinical guideline for gastrointestinal stromal tumors (2022)
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-26T23%3A34%3A57IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=SEOM-GEIS%20clinical%20guideline%20for%20gastrointestinal%20stromal%20tumors%20(2022)&rft.jtitle=Clinical%20&%20translational%20oncology&rft.au=Serrano,%20C%C3%A9sar&rft.date=2023-09-01&rft.volume=25&rft.issue=9&rft.spage=2707&rft.epage=2717&rft.pages=2707-2717&rft.issn=1699-3055&rft.eissn=1699-3055&rft_id=info:doi/10.1007/s12094-023-03177-7&rft_dat=%3Cproquest_pubme%3E2808588153%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c447t-cb238733d5f1860dd895741c3f98ddef73283404977a4de6d4760d69e2b3fd4f3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2808588153&rft_id=info:pmid/37129716&rfr_iscdi=true